RIGEL PHARMACEUTICALS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
RIGEL PHARMACEUTICALS, INC. (RIGL) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $6.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-04
- RIGEL PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $6.90M, a 107.39% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.49M, a 3.87% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.41M, a 27.44% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.33M, a 31.08% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $12.90M, a 3.33% increase from fiscal 2024.
- RIGEL PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $12.48M, a 40.98% increase from fiscal 2023.
- RIGEL PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $8.85M, a 29.23% decline from fiscal 2022.
- RIGEL PHARMACEUTICALS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $12.51M, a 30.52% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.90M 10-Q · filed 2026-08-04 | $10.39M derived: sum of 2 quarters · filed 2026-08-04 | ||
| 2026-03-31 | $3.49M 10-Q · filed 2026-08-04 | |||
| 2025-12-31 | $12.90M 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $3.41M 10-Q · filed 2025-11-04 | $6.74M derived: sum of 2 quarters · filed 2026-08-04 | $10.10M derived: sum of 3 quarters · filed 2026-08-04 | |
| 2025-06-30 | $3.33M 10-Q · filed 2026-08-04 | $6.69M derived: sum of 2 quarters · filed 2026-08-04 | ||
| 2025-03-31 | $3.36M 10-Q · filed 2026-08-04 | |||
| 2024-12-31 | $12.48M 10-K · filed 2026-03-03 | |||
| 2024-09-30 | $2.68M 10-Q · filed 2025-11-04 | $5.22M derived: sum of 2 quarters · filed 2025-11-04 | $10.36M derived: sum of 3 quarters · filed 2025-11-04 | |
| 2024-06-30 | $2.54M 10-Q · filed 2025-11-04 | $7.68M derived: sum of 2 quarters · filed 2025-11-04 | ||
| 2024-03-31 | $5.14M 10-Q · filed 2025-11-04 | |||
| 2023-12-31 | $8.85M 10-K · filed 2026-03-03 | |||
| 2023-09-30 | $1.96M 10-Q · filed 2024-11-07 | $4.14M derived: sum of 2 quarters · filed 2024-11-07 | $6.91M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $2.19M 10-Q · filed 2024-11-07 | $4.95M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $2.77M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $12.51M 10-K · filed 2025-03-04 | |||
| 2022-09-30 | $2.73M 10-Q · filed 2023-11-07 | $5.17M derived: sum of 2 quarters · filed 2023-11-07 | $8.41M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $2.44M 10-Q · filed 2023-11-07 | $5.68M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $3.24M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $9.59M 10-K · filed 2024-03-05 | |||
| 2021-09-30 | $2.24M 10-Q · filed 2022-11-03 | $4.54M derived: sum of 2 quarters · filed 2022-11-03 | $7.21M derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $2.31M 10-Q · filed 2022-11-03 | $4.98M derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | $2.67M 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $7.39M 10-K · filed 2023-03-07 | |||
| 2020-09-30 | $1.91M 10-Q · filed 2021-11-02 | $3.69M derived: sum of 2 quarters · filed 2021-11-02 | $5.74M derived: sum of 3 quarters · filed 2021-11-02 | |
| 2020-06-30 | $1.78M 10-Q · filed 2021-11-02 | $3.83M derived: sum of 2 quarters · filed 2021-11-02 | ||
| 2020-03-31 | $2.05M 10-Q · filed 2021-11-02 | |||
| 2019-12-31 | $9.21M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | $2.11M 10-Q · filed 2020-11-05 | $4.80M derived: sum of 2 quarters · filed 2020-11-05 | $7.79M derived: sum of 3 quarters · filed 2020-11-05 | |
| 2019-06-30 | $2.69M 10-Q · filed 2020-11-05 | $5.68M derived: sum of 2 quarters · filed 2020-11-05 | ||
| 2019-03-31 | $2.99M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $7.76M 10-K · filed 2021-03-02 | |||
| 2018-09-30 | $3.01M 10-Q · filed 2019-11-05 | $4.14M derived: sum of 2 quarters · filed 2019-11-05 | $5.68M derived: sum of 3 quarters · filed 2019-11-05 | |
| 2018-06-30 | $1.13M 10-Q · filed 2019-11-05 | $2.67M derived: sum of 2 quarters · filed 2019-11-05 | ||
| 2018-03-31 | $1.54M 10-Q · filed 2019-11-05 | |||
| 2017-12-31 | $5.99M 10-K · filed 2020-02-27 | |||
| 2016-12-31 | $7.83M 10-K · filed 2019-02-28 | |||
| 2015-12-31 | $7.40M 10-K · filed 2018-03-06 | |||
| 2014-12-31 | $9.79M 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |